Quotes 5-day view Delayed Nasdaq
05/16/2022
05/17/2022
05/18/2022
05/19/2022
05/20/2022
Date
22.28(c)
23.09(c)
22.71(c)
24.93(c)
24.36 Last
770 105
658 273
919 849
1 089 901
740 901 Volume
-1.55% +3.64% -1.65% +9.78% -2.29% Change
Estimated financial data (e) (USD)
Sales 2022
1 548 M - -
Net income 2022
314 M - -
Net cash position 2022
2 110 M - -
P/E ratio 2022
10,8x
Yield 2022
-
Sales 2023
307 M - -
Net income 2023
-338 M - -
Net cash position 2023
1 797 M - -
P/E ratio 2023
-10,2x
Yield 2023
-
Capitalization
3 300 M 3 300 M -
EV / Sales 2022
0,77x
EV / Sales 2023
4,89x
Nbr of Employees
444
Free-Float
86,6%
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of...
Ratings of Vir Biotechnology, Inc.
All news about VIR BIOTECHNOLOGY, INC.
04:11p VIR BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Mat..AQ
05/18 Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details GL
05/18 Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details AQ
05/12 HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R.. MT
05/11 Pfizer's $11.6 billion Biohaven buy could spark more biotech deals RE
05/05 Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81.. MT
05/05 VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. AQ
05/05 Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81.. MT
05/05 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. GL
05/05 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. AQ
05/05 Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, .. CI
05/02 INSIDER SELL : Vir BiotechnologyMT
04/27 TRANSCRIPT : Vir Biotechnology, Inc. - Special CallCI
04/27 Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa.. GL
04/27 Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa.. GL
News in other languages on VIR BIOTECHNOLOGY, INC.
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
Chart VIR BIOTECHNOLOGY, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
24,93 $
Average target price
53,29 $
Spread / Average Target
114%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
